CICigna Corporation
Cigna Corporation (CI) is a health insurance and managed care provider with a broad footprint in the U.S. health care system, offering employer-sponsored and individual health plans, pharmacy benefits, and specialty services. The next catalyst is Nov 5, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to sustain growth in its pharmacy and specialty drug businesses amid rising medical costs and regulatory pressures.
- Revenue reached $277.09B in 2026, up 11.2% YoY, with net income of $6.17B and free cash flow of $3.55B.
- Margins remain tight at 2.2% net margin, but leverage is moderate at 0.95x debt-to-equity.
- Shareholders’ equity stands at $41.71B, with a diluted EPS of $6.29.
The schedule
- Wed20Jan
The event will test how Cigna navigates potential regulatory changes and legislative actions impacting its PBM operations, which could affect its revenue and profitability.
- Thu4Feb
This release will test Cigna's ability to sustain growth in its PBM and specialty pharmacy lines, particularly amid regulatory scrutiny and pricing pressures, which differs from the last print where the focus was on short-term revenue.
- Tue30Mar
The event will test Cigna's ability to validate the growth potential of its specialty pharmacy and GLP-1 segments, which could impact its long-term revenue and market position.
- Thu6May
The release will test Cigna's ability to maintain its growth trajectory in the face of macroeconomic headwinds and regulatory headwinds, particularly in its specialty pharmacy and GLP-1 segments, which differ from the last print where the focus was on short-term revenue.
- Thu5Aug
This release will test Cigna's ability to sustain its growth in a more mature market, particularly in its PBM and specialty pharmacy lines, which differ from the last print where the focus was on short-term revenue.
- Thu30Sep
The event will test Cigna's ability to communicate its long-term strategy and growth prospects to investors, which could impact its stock price and market perception.
- Thu4Nov
Past
- Thu5Nov
Actual outcome: Bear
Cigna reported an EPS actual of 25.24, matching the estimate, but the stock fell 2.6% as investors focused on weaker-than-expected guidance for specialty pharmacy and PBM segments, which failed to meet expectations for top-line growth and margin expansion. The lack of clarity on long-term growth prospects and margin pressure overshadowed the earnings beat, pushing the stock below the bear floor.
The earnings release will test whether Cigna can deliver strong top-line growth and margin expansion, particularly in its specialty pharmacy and PBM segments, which differ from the last print where guidance was overly optimistic.
- Thu7May
Actual outcome: Bull · $299.16 at outcome
Cigna delivered strong Q1 results, beating adjusted EPS estimates ($7.79 vs $7.62) and reporting a 5% increase in total revenues driven by 9% growth in its Evernorth unit. The company also raised its full-year 2026 adjusted EPS outlook to at least $30.35 and announced plans to exit the ACA individual exchange market to focus on core businesses, reinforcing the bullish fundamental case despite a muted initial price reaction.
- Sun15Mar
Actual outcome: Mixed · $270.36 at outcome
The stock remained flat following the CMS announcement as the final 2027 Medicare Advantage payment rates likely met baseline expectations without providing a positive surprise to offset broader sector headwinds. While Cigna's Evernorth segment continues to drive strong revenue growth and management has a history of earnings beats, persistent concerns regarding rising medical costs and conservative 2026 guidance kept the price centered between the bull and bear targets.
- Thu5Feb
Actual outcome: Bull · $287.61 at outcome
The outcome was bullish as Cigna reported a Q4 2025 adjusted EPS beat ($8.08 vs. $7.88 estimate) and strong full-year revenue growth, alongside a "modestly higher 2026 earnings outlook." Management commentary addressed key concerns regarding medical cost trends and highlighted continued strength in the Evernorth segment, validating the company's low P/E valuation thesis. This strong fundamental performance drove the stock past the $288 bull target.
Scouting Reports

Brent Breaks $95: Testing the E&P Capital Discipline Pledge
Nov 5, 2026
Broad markets celebrated the midterm election gridlock on Wednesday, sending the Dow up 1,500 points on the assumption that a divided Washington means a pause on transformative economic policy. But th
Read more →
Weekly Playbook: Monetizing the Outpatient Migration (CARE, CI, CON)
Nov 1, 2026
The structural shift from expensive inpatient hospital beds to high-efficiency ambulatory care is a massive reallocation of capital. As the aging population demands more frequent, lower-acuity interve
Read more →
Weekly Playbook: Pricing the Ambulatory Care Boom (SYK, CYH, FTRE)
Oct 25, 2026
The demographic shift toward an aging population is steadily forcing healthcare out of expensive inpatient wards and into ambulatory settings. The "Aging Population Drives Growth in Ambulatory Care" t
Read more →